Notification of Annual General Meeting and Extraordinary General Meeting
12 June 2008 - 7:50AM
PR Newswire (US)
VALLEY COTTAGE, New York, June 11 /PRNewswire-FirstCall/ -- XTL
Biopharmaceuticals Ltd. (NASDAQ:XTLB)(TASE:XTL) today announced a
notice convening its Annual General Meeting ("AGM") and
Extraordinary General Meeting ("EGM"). The AGM and EGM will take
place at the Conference Room at the Company's Israeli offices at
Building 3, Kiryat Weizmann Science Park, Rehovot, Israel 76100, at
4:00 p.m. Israel time, and 4:30 p.m. Israel time, respectively, on
July 17, 2008. At the AGM it is proposed that: -- the annual report
and financial statements for the year ended December 31, 2007 be
received; -- Kesselman & Kesselman (PricewaterhouseCoopers) be
reappointed as the Company's auditors and the fixing of their
remuneration be authorized; and -- Messrs Michael Weiss, Ben Zion
Weiner, William Kennedy, and Laurence Charney be re-appointed as
Directors of the Company. At the EGM it is proposed that: -- the
grant of options to Michael Weiss and Ben-Zion Weiner as detailed
in the Notice be approved; -- the grant of options to Ben-Zion
Weiner and William Kennedy as detailed in the Notice be approved;
and -- the remuneration terms for Laurence Charney as detailed in
the Notice be approved. The Notice of the AGM and EGM is available
for the public at the US Securities Exchange Edgar site:
http://www.sec.gov/ and at the Israel Securities Authority's site:
http://www.magna.isa.gov.il/ . ABOUT XTL BIOPHARMACEUTICALS LTD.
XTL Biopharmaceuticals Ltd. ("XTL") is engaged in the development
of therapeutics for the treatment of diabetic neuropathic pain and
HCV. XTL is developing Bicifadine, a serotonin and norepinephrine
reuptake inhibitor, for the treatment of diabetic neuropathic pain,
which is currently in a Phase 2b study. XTL has out-licensed its
novel pre-clinical HCV small molecule inhibitor program. XTL also
has an active in-licensing and acquisition program designed to
identify and acquire additional drug candidates. XTL is publicly
traded on the NASDAQ and Tel-Aviv Stock Exchanges
(NASDAQ:XTLB)(TASE:XTL). DATASOURCE: XTL Biopharmaceuticals Ltd.
CONTACT: Ron Bentsur, Chief Executive Officer, XTL
Biopharmaceuticals Ltd., +1-845-267-0707 ext. 225
Copyright
XTL Biopharmaceuticals (NASDAQ:XTLB)
Historical Stock Chart
From Jun 2024 to Jul 2024
XTL Biopharmaceuticals (NASDAQ:XTLB)
Historical Stock Chart
From Jul 2023 to Jul 2024